Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amodiaquine for treating malaria.

P Olliaro1, P Mussano

  • 1TDR, World Health Organization, 20, avenue Appia, 1211 Genève 27, Switzerland. olliaro@who.ch

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of mint virus C, a new member of the genus Carlavirus.

Archives of virology·2025
Same author

Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs.

International journal for parasitology. Drugs and drug resistance·2020
Same author

Building the capacity of public health programmes to become data rich, information rich and action rich.

Public health action·2018
Same author

Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.

CPT: pharmacometrics & systems pharmacology·2014
Same author

Leishmaniasis chemotherapy--challenges and opportunities.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011
Same author

Hypoxia modulates the effect of dihydroartemisinin on endothelial cells.

Biochemical pharmacology·2011
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Amodiaquine effectively clears malaria parasites compared to chloroquine. While generally safe for uncomplicated malaria, ongoing monitoring for drug resistance and toxicity is recommended.

Area of Science:

  • Tropical medicine
  • Pharmacology
  • Infectious diseases

Background:

  • Amodiaquine is a widely used antimalarial drug.
  • Concerns exist regarding fatal adverse drug reactions, prompting review of its use.

Purpose of the Study:

  • To assess the efficacy and safety of amodiaquine for malaria treatment.
  • To compare amodiaquine with other antimalarial drugs.

Main Methods:

  • Systematic review of randomized and quasi-randomized controlled trials.
  • Searched Cochrane Infectious Diseases Group trials register and Medline.
  • Independent data extraction and quality assessment by two reviewers.

Main Results:

  • Amodiaquine demonstrated superior parasite clearance rates compared to chloroquine.

Related Experiment Videos

  • Parasite clearance at 7 days was 83% for amodiaquine vs. 56% for chloroquine.
  • No significant differences in adverse events were found between amodiaquine, chloroquine, and sulfadoxine/pyrimethamine.

    • Conclusions:

    • Evidence supports amodiaquine's continued use for uncomplicated malaria.
    • Consideration of drug resistance and continued toxicity monitoring are essential.
    • Adverse effects reported were generally minor or moderate.